

Technology Appraisal Committee A Interests Register

Topic: Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

Publication Date: 16 July 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Patrick de Barr	TAC A Committee Member	Direct - Financial	Patrick works for GSK who market dostarlimab, a competitor product in endometrial carcinoma	09/01/2025	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal.
Hugo Pedder	TAC A Committee Member	Direct - Financial	I have done consultancy work in the last 12 months on behalf of Baxter Healthcare on a treatment and indication unrelated to the current appraisal, for which I received payment.	09/01/2025	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.
Dominic Pivonka	TAC A Committee Member	Financial Interests	Dominic's employer (AbbVie) has a treatment being evaluated for endometrial cancer in phase 1	14/01/2025	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Gracey Remmington Teeling	Patient Expert	Direct Financial	Ms Remmington Teeling is a member of GSK Global Womb Cancer Council, in a patient expert capacity. She received approximately £400 per meeting which are quarterly. She recently received approx. £1400 from GSK for taking part in additional activities such as a film about patient engagement and providing patient insight at a conference.	04/02/2025	It was agreed that Ms Remmington Teeling's declaration would not prevent her from providing expert advice to the committee.
Dr Gemma Eminowicz	Clinical Expert	Direct Financial	<p>Consulting and advisory board fees from MSD, Eisai and GSK:</p> <p>GSK Advisory boards – April and June 2024</p> <p>Consultancy contract with MSD started October 2023 working on real world endometrial cancer data and PRO reporting. Total income in past 1 year £652.40.</p> <p>MSD advisory board July 2024 on first line advanced endometrial cancer treatment and role of</p>	04/02/2025	It was agreed Dr Eminowicz's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>pembrolizumab/dostarlimab – fee to be paid £1344</p> <p>Consultancy contract with Eisai started focusing on information leaflet production etc</p>		
Dr Emma Hudson	Clinical Expert	Direct Financial	<p>Advisory board AZ</p> <p>Meeting sponsorship by GSK</p>	04/02/2025	It was agreed Dr Hudson's declaration would not prevent her from providing expert advice to the committee.